Abstract: Disclosed herein are stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Celecoxib, its salts, or derivatives thereof, which is useful in the treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain especially in cancer related acute pain, primary dysmenorrhea. More specifically, the complexes possess instantaneous redispersibility, increased apparent solubility and permeability that provide faster onset of action for acute pain relief and lower GI related side effects. Further disclosed are methods of formulating and manufacturing the complexes described herein, pharmaceutical compositions, and uses and methods of treatment.
Type:
Grant
Filed:
April 23, 2019
Date of Patent:
June 23, 2020
Assignee:
NanGenex Nanotechnology Incorporated
Inventors:
Erzsébet Réka Angi, Tamás Jordán, Richárd Balázs Kárpáti, Gergo Patyi, Orsolya Basa-Dénes, Tamás Solymosi, Zsolt Ötvös, László Molnár, Hristos Glavinas, Genovéva Filipcsei
Abstract: Disclosed herein are pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt or derivative thereof, together with complexation agents and pharmaceutically acceptable excipients; processes for the preparation thereof; and pharmaceutical compositions containing them. The complexes possess instantaneous redispersibility, increased apparent solubility and permeability compared to KALYDECO, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex Ivacaftor in solution form.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
June 9, 2020
Assignee:
NanGenex Nanotechnology Incorporated
Inventors:
Richárd Balázs Kárpáti, Gergo Patyi, Orsolya Basa-Dénes, Erzsébet Réka Angi, Tamás Jordán, Tamás Solymosi, Hristos Glavinas, Genovéva Filipcsei
Abstract: The present disclosure relates to pharmaceutically acceptable complex formulae comprising complexes of Abiraterone acetate and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present disclosure have improved physicochemical properties which results in reduced food effect which allows significant dose reduction and the abandoning of the requirement of taking the drug on an empty stomach.
Type:
Grant
Filed:
October 17, 2018
Date of Patent:
June 2, 2020
Assignee:
NanGenex Nanotechnology Incorporated
Inventors:
Réka Angi, Tamás Jordán, Orsolya Basa-Dénes, Tamás Solymosi, Zsolt Ötvös, Hristos Glavinas, Genovéva Filipcsei
Abstract: The subject of the invention is the (50) continuous flow system for the synthesis of nanoparticles which consist of the (1a) feeding unit connected to the flow path, at least one (2) first reactor unit possessing the (13) heatable reactor-zone, the (3) second reactor unit which follows (2) in the same cascade; the (5) mixing unit and the (1b) second feeding unit between (2) and (3) reactor units, the (9) and (10) feeding pumps connected to the raw material source and/or (22) control unit which is capable of controlling at least one (18) pressure controller and/or controlling the temperature of at least one (13) heatable reactor-zone; each (13) heatable reactor-zone is followed by (14) cooling unit in the cascade. In addition, the subject of this invention is a process for the synthesis of nanoparticles, preferably metal-containing nanoparticles, and nanoparticles of biologically active organic molecules wherein the process is accomplished in the device according to FIG. 1.
Type:
Application
Filed:
April 28, 2009
Publication date:
May 5, 2011
Applicant:
Nangenex Nanotechnology Incorporated
Inventors:
Krisztián Niesz, Attila Wootsch, Maxime Groualle, Zsolt Ötvös, Ferenc Darvas